Zhi Tong Cai Jing·2025-08-08 02:57Group 1 - Junshi Biosciences (01877) experienced a significant stock price increase, rising over 11% at one point, following a previous surge of over 33% on August 5 [1] - As of the report, the stock is up 8.14%, trading at HKD 29.5, with a trading volume of HKD 531 million [1] - The company completed a placement of 41 million new shares on June 20, raising approximately HKD 1.026 billion, with 70% of the funds allocated for innovative drug research and 30% for general corporate purposes [1] Group 2 - Junshi Biosciences plans to use the raised funds for the development of various drug candidates, including PD-1/VEGF bispecific antibodies, EGFR/HER3 ADC, and PD-1/IL-2 fusion proteins [1] - According to a report from Founder Securities, JJS207 has significant business development (BD) potential, as international pharmaceutical companies are interested in PD-1/VEGF products [1] - Open Source Securities noted that by May 2025, only Pfizer and Merck have entered this market segment among multinational corporations, suggesting that other early-stage PD-(L)1/VEGF bispecific antibodies from China may have opportunities for international business development as data matures [1]